ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 979

HLA Class I Genes As Susceptibility Markers of Psoriatic Arthritis in Patients with Psoriasis – a Meta-Analysis

Lihi Eder1, Fatima Abji2, Cheryl Rosen3, Muhammad Haroon4, Vinod Chandran1, Rubén Queiro5, Shelley Bull6, Richard J. Cook7, Proton Rahman8, Robert Winchester9, Oliver FitzGerald10 and Dafna D. Gladman1, 1Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, 2University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, 3Dermatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, 4Kerry General Hospital, Tralee, Ireland, 5Rheumatology Service, Hospital Universitario Central de Asturias, Oviedo, Spain, 6School of Public Health, Mount Sinai Hospital, Toronto, ON, Canada, 7Statistics and Actuarial Science, University of Waterloo, Waterloo, ON, Canada, 8Computer Sciences, Memorial University of Newfoundland, St. John's, NF, Canada, 9Columbia University, New York, NY, 10Department of Rheumatology, St Vincent's University Hospital, Dublin, Ireland

Meeting: 2015 ACR/ARHP Annual Meeting

Date of first publication: September 29, 2015

Keywords: Genetic Biomarkers, human leukocyte antigens (HLA), psoriasis, psoriatic arthritis and risk

  • Tweet
  • Email
  • Print
Session Information

Date: Sunday, November 8, 2015

Title: Spondylarthropathies Psoriatic Arthritis - Pathogenesis, Etiology

Session Type: ACR Concurrent Abstract Session

Session Time: 2:30PM-4:00PM

Background/Purpose:

Genes that differentiate patients with psoriatic arthritis (PsA) from those with psoriasis alone may serve as markers for the development of PsA in psoriasis patients. Psoriatic disease risk is strongly associated with variation within the HLA class I region. In this large-scale study we aimed to strengthen evidence about previously reported HLA risk alleles for PsA and to identify novel susceptibility markers to the disease.

Methods:

1677 PsA, 702 psoriasis without arthritis and 2275 healthy controls of European ethnicity from 4 sites in Canada, Ireland and Spain were included in the study. HLA-B and –C alleles were genotyped using sequence specific primers. Differences in allelic distribution for each HLA locus were compared using the Likelihood Ratio test by regression models with site indicator. The False Discovery Rate (FDR) approach was employed to assess the impact of multiple testing. Logistic regression analysis was performed to account for linkage disequilibrium between HLA-B and -C alleles. The association between amino acids encoded by the identified HLAgenes and PsA was assessed using logistic regression analysis.

Results:

The following HLA alleles were confirmed as independent susceptibility markers of PsA in psoriasis patients in the multivariate analysis: B*08 (Odds Ratio (OR) 1.48, p=0.002), B*27 (OR 3.69, p=2.8×10-12), B*38 (OR 1.68, p=0.005), B*39 (OR 1.80, p=0.01) and C*06 (OR 0.47, p=6.8×10-13). The following HLA alleles were confirmed as susceptibility markers for PsA in the general population: B*27 (OR 2.37, p=2.5×10-13), B*38 (OR 3.81, p=2.5×10-13), B*39 (OR 2.17, p=9.5×10-6), B*57 (OR 2.06, p=3.6×10-7) and C*06 (OR 1.29, p=0.02). The frequency of the following alleles was reduced in PsA compared to healthy controls: B*07, B*44, B*40, B*15, B*49, B*51, B*55, C*04 and C*08. PsA susceptibility was also associated with the presence of cysteine at position 67 (B*27, B*39, B*38), methionine at position 67 (B*57), aspartate at position 9 (B*08) and glutamine at position 45 (B*08, B*39, B*38, B*27). However, after inclusion of the specific HLA risk alleles these associations were not statistically significant.

Conclusion:

PsA susceptibility is associated with several HLA class I alleles. HLA-B*38, B*39, B*08 and B*27 confer an increased risk for PsA compared to psoriasis. In contrast, HLA-C*06, the strongest psoriasis susceptibility gene, is associated with a lower risk of developing PsA in patients with psoriasis.


Disclosure: L. Eder, None; F. Abji, None; C. Rosen, None; M. Haroon, None; V. Chandran, None; R. Queiro, None; S. Bull, None; R. J. Cook, None; P. Rahman, None; R. Winchester, None; O. FitzGerald, None; D. D. Gladman, None.

To cite this abstract in AMA style:

Eder L, Abji F, Rosen C, Haroon M, Chandran V, Queiro R, Bull S, Cook RJ, Rahman P, Winchester R, FitzGerald O, Gladman DD. HLA Class I Genes As Susceptibility Markers of Psoriatic Arthritis in Patients with Psoriasis – a Meta-Analysis [abstract]. Arthritis Rheumatol. 2015; 67 (suppl 10). https://acrabstracts.org/abstract/hla-class-i-genes-as-susceptibility-markers-of-psoriatic-arthritis-in-patients-with-psoriasis-a-meta-analysis/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2015 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/hla-class-i-genes-as-susceptibility-markers-of-psoriatic-arthritis-in-patients-with-psoriasis-a-meta-analysis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology